You can buy or sell KYMR and other stocks, options, and ETFs commission-free!
Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA. The listed name for KYMR is Kymera Therapeutics, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Feb 11, Pre-Market